Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
Open accessThe DOI matches its Crossref record; 32 of the 35 references it cites were found in a registry or an index.
Abstract
PURPOSE: An important factor in the choice of therapy is the impact it has on the patient's quality of life. This survey aimed to understand treatment burden, treatment-related anxiety and worry, and practical issues such as appointment attendance and work absence in patients receiving injection therapy for diabetic macular edema (DME) or retinal vein occlusion (RVO). PATIENTS AND METHODS: A European sample of 131 retinal patients completed a detailed questionnaire to elucidate the impact of injection therapy on individuals with DME or RVO. RESULTS: RVO and DME greatly impact a patient's quality of life. An intensive injection regimen and the requirements for multiple hospital visits place a large practical burden on the patient. Each intravitreal injection appointment (including travel time) was reported to take an average of 4.5 hours, with a total appointment burden over 6 months of 13.5 hours and 20 hours for RVO and DME patients, respectively. This creates a significant burden on patient time and may make appointment attendance difficult. Indeed, 53% of working patients needed to take at least 1 day off work per appointment and 71% of patients required a carer's assistance at the time of the injection appointment, ~6.3 hours per injection. In addition to practical issues, three-quarters of patients reported experiencing anxiety about their most recent injection treatment, with 54% of patients reporting that they were anxious for at least 2 days prior to the injection. Patients' most desired improvement to their treatment regimen was to have fewer injections and to require fewer appointments, to achieve the same visual results. CONCLUSION: Patients' quality of life is clearly very affected by having to manage an intensive intravitreal injection regimen, with a considerable treatment burden having a large negative effect. Reducing the appointment burden to achieve the same visual outcomes and the provision of additional support for patients to attend appointments would greatly benefit those receiving intravitreal injection therapies for DME and RVO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the effectiveness of anti-VEGF injections in stabilizing and, even in some cases, reversing these conditions demonstrated in clinical trials [10], their high price compounded with their long-term associated care represent a strain on health systems and patients [11–13].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The repeated injections may take a significant toll on the patients’ emotional wellbeing and quality of life [11, 69], adversely affecting adherence and potentially leading to undertreatment and deterioration of the condition [70].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985 · cited 1×
“5% of patients with diabetes worldwide.(1) Globally, 26.”
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,326
Boyer, D. S., Yoon, Y. H., Belfort, R., Bandello, F., Maturi, R. K., Augustin, A. J., Li, X.-Y., Cui, H., Hashad, Y., & Whitcup, S. M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.04.024 · Cited by 1,122
Brown, D. M., Nguyen, Q. D., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Schlottmann, P. G., Rundle, A. C., Zhang, J., Rubio, R. G., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.02.034 · Cited by 830
Intravitreal Aflibercept for Diabetic Macular Edema
Korobelnik, J.-F., Do, D. V., Schmidt-Erfurth, U., Boyer, D. S., Holz, F. G., Heier, J. S., Midena, E., Kaiser, P. K., Terasaki, H., Marcus, D. M., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.006 · Cited by 816
The Impact of Comorbid Chronic Conditions on Diabetes Care
Piette, J. D., & Kerr, E. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-2078 · Cited by 731 · cited 2×
“an already demanding workload and who can only spend a limited amount of time with each patient.(22,40)”
The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study.
Klein, R., Klein, R., Moss, S. E., & Meuer, S. M. (2000) · PubMed · Cited by 636
Intravitreal Aflibercept for Diabetic Macular Edema
Brown, D. M., Schmidt-Erfurth, U., Do, D. V., Holz, F. G., Boyer, D. S., Midena, E., Heier, J. S., Terasaki, H., Kaiser, P. K., Marcus, D. M., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.06.017 · Cited by 623
Current Epidemiology of Diabetic Retinopathy and Diabetic Macular Edema
Ding, J., & Wong, T. Y. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0283-6 · Cited by 439 · cited 1×
“In the future, DME is set to increase as a public health problem due to aging populations in Europe, Africa, and the Middle East and the increased prevalence of diabetes, longer duration of diabetes, and older age at onset.(3,4) RVO is also an important and growing cause of vision loss, and after diabetic retinopathy,…”
Research works printed but not linked: 1
- [13]Weinberg DV Seddon JM Venous occlusive diseases of the retina Albert DM Jakobiec FA Principles and Practice of Ophthalmology 2 Philadelphia W.B. Saunders Company 1994 735 746
Cited by
Weiss, M., Sim, D. A., Herold, T., Schumann, R. G., Liegl, R., Kern, C., Kreutzer, T., Schiefelbein, J., Rottmann, M., Priglinger, S., et al. (2018) · Retina · doi:10.1097/iae.0000000000001892 · Cited by 155
“Sex (%) 45 men (41), 64 women (59) 87 men (64), 49 women (36) ,0.”
Coarse-to-fine classification for diabetic retinopathy grading using convolutional neural network
Wu, Z., Shi, G., Chen, Y., Shi, F., Chen, X., Coatrieux, G., Yang, J., Luo, L., & Li, S. (2020) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2020.101936 · Cited by 140
“Experimental results show that proposed CF-DRNet outperforms the comparative methods [6, 19] in the IDRiD database and Kaggle database.”
DMENet: Diabetic Macular Edema diagnosis using Hierarchical Ensemble of CNNs
Singh, R. K., & Gorantla, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0220677 · Cited by 97
Augustin, A. J., Bopp, S., Fechner, M., Holz, F. G., Sandner, D., Winkgen, A., Khoramnia, R., Neuhann, T. F., Warscher, M., Spitzer, M. S., et al. (2019) · European Journal of Ophthalmology · doi:10.1177/1120672119834474 · Cited by 74
Eter, N., Singh, R. P., Abreu, F. M., Asik, K., Basu, K., Baumal, C. R., Chang, A., Csaky, K. G., Hašková, Z., Lin, H., et al. (2021) · Ophthalmology Science · doi:10.1016/j.xops.2021.100111 · Cited by 86
“The burden of intravitreal anti-VEGF monotherapy and need for frequent clinic visits for treatment, monitoring, or both is high for patients with DME, their caregivers, and health care providers.(27,28) Despite the efficacy shown with intravitreal anti-VEGF monotherapy in clinical trials with monthly visits, many pati…”
Metadata
- Authors
- Sivaprasad, S., & Oyetunde, S.
- Affiliations
- NIHR Moorfields Biomedical Research Centre (GB)
- Allergan (United Kingdom) (GB)
- Corresponding author
- Sivaprasad, Sobha
- ORCID
- Sivaprasad, Sobha
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2016-05
- Volume
- 10
- Pages
- 939
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- PMC
- PMC4888735
- OpenAlex
- W2394715476
- Cited by
- 134
- References
- 35
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 15 · 2023: 13 · 2022: 10 · 2021: 14 · 2020: 16 · 2019: 6 · 2018: 10 · 2017: 9
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical ophthalmology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- diabetic macular edema, retinal vein occlusion, intravitreal injection, treatment burden, quality of life, treatment-related anxiety, absenteeism, appointment attendance, caregiver support, patient preferences
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. https://app.cochat.ai/papers/10.2147/opth.s100168
- The paper
- Sivaprasad, S., & Oyetunde, S. (2016). Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clinical Ophthalmology. https://doi.org/10.2147/opth.s100168
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.